Open Access Research Article

Observations on Prescribed Drugs for Pain Patients

Agnes Cua, Kevin Krock, Richard Thomas, and Amadeo J Pesce*

Precision Diagnostics LLC, San Diego, CA, USA

Corresponding Author

Received Date: August 09, 2023;  Published Date: September 18, 2023

Abstract

Background: The Clinical Laboratory Institute has Published guidelines for testing drugs in urine to monitor compliance.

Objective: We wished to compare our observations on the frequency of positive drug use from our urine test data with the panel of tests recommended by CLSI C-63 Laboratory Support for Pain Management programs.

Study Design: We examine the frequency of positive drug test data from 2016 to 2022 from medical practices designated as pain. Setting: Reference laboratory performing urine drug testing for pain practices.

Methods: Our test menu differed from the more exhaustive one listed in the CLSI document. Results: there was good correlation with those drugs prescribed for pain, but not for the psychotropic ones as many were not included in our test panel. We found several drugs taken by patients that were not listed in the CLSI document.

Limitations: Our comparison was limited by our 80-drug test menu.

Conclusion: The CLSI document offers guidance, but the list must be tailored for the practices served by the laboratory.

Keywords:Pain patients; Drug therapy; Urine drug testing

Background

The CLSI (Clinical Laboratory Standards Institute) has proposed a list of drugs that should be tested for their presence to ensure patient compliance with their pain medications [1]. We wished to compare the CLSI recommendations with our observed positive drug tests in this population. We offer a panel of 80 drugs and metabolites in our definitive urine drug test [2]. For this analysis we matched the medical practice designation with the drugs observed by urine drug testing. The data is from our laboratory which performs drug testing for pain clinics and rehabilitation centres. This correlation should result in a good indicator of the drugs used in the medical practice of treating these patients. The CLSI recommendations and our observations should correlate.

Study Design

Permission to perform the study was granted from WCG IRB WCG IRB, 1019 39th Ave., SE Suite 120, Puyallup, WA 98374, USA. The patient population was selected from those medical practices designated as pain medicine [3,4]. This included pain/ortho, pain management, primary care pain, internal medicine, primary family medicine, pain orthopedics, physical medicine and pain, sports medicine.

Methods

The laboratory tested 611,329 specimens from 2016 to 2022. The method of analysis was that of Krock K, et al. [3]. The computational methods and data storage were that of Pesce AJ, et al. [2]. The medical practice designations were obtained from our billing information. The calculation of observed frequency was based on the number of times that drug was observed in the years 2020 to 2022.

Results

The tier 1 drugs in the CLSI document that we test for are Amphetamine, Methamphetamine, Methylenedioxymethamphetamine (MDMA), Methylenedioxyamphetamine (MDA), Methylenedioxyethylamphetamine, (MDEA), Phenobarbital, Alprazolam, Clonazepam, Diazepam, Lorazepam, Oxazepam, Temazepam, Benzoylecgonine, Δ9-tetrahydrocannabinol (THC), 6-acetylmorphine (6-AM), Buprenorphine, Codeine, Fentanyl, Hydrocodone, Hydromorphone, Morphine, Oxycodone, Oxymorphone, Tapentadol, and Tramadol. Not included in the CLSI document are the metabolites norhydrocodone, noroxycodone, 7-aminoclonazepam, alpha-hydroxyalprazolam, o-desmethyl tramadol, and norbuprenorphine which are used to indicate that the patients are taking the prescribed drug.

For the pain medication patients, the observed drug positive finding for each medication is tabulated in Table 1. The list is truncated at forty-six observations. The lowest frequency is about 2.5% of the most prevalent treating drug, hydromorphone, The next most prevalent was oxycodone. Hydrocodone was the third most prevalent. The oxymorphone frequency was due to its role as a metabolite of oxycodone as well as being a separate prescribed drug. Gabapentin was also prevalent as a pain medication. The illicit drug fentanyl was present in less than 10% of our observations. However, THCA was present in about 25% of our positive specimens.

Table 1:Pain Management testing, From CLSI Table 8: Tiers of drug testing.

irispublishers-openaccess-addiction-psychology

The drug propoxyphene was observed infrequently as this has been removed by the FDA as a prescription drug. However, alcohol use must be considered in pain management testing. In this case about 23% of the positive specimens were positive for the alcohol use maker ethyl sulfate.

Discussion

For the pain medications we expected hydrocodone to be the most prevalent prescribed drug as this was the most prescribed opiate in the general population.

There are a number of available surveys showing the most prescribed drugs in the US population. These are Vitamin D, Amoxicillin, Levothyroxine, Lisinoprill, Ibuprofen, Amphetamine/ dextroamphetamine, Amlodipine, Albuterol HFA, Prednisone, and Gabapentin [5]. These observations are based on population prescribing information and may not reflect what drugs are being prescribed for specific medical conditions. It is possible to establish specific drugs used to treat medical conditions by examining the medical practices. Pain management is somewhat unique because most of the patients undergo urine drug testing. We decided to examine the drug treatment of patients being given medications for pain management. We postulate that the information of drug test results may constitute a more accurate estimation of the actual patient’s use of their prescriptions but may also reveal nonprescription drug use.

We chose to examine the presence of this drug and other opiates in pain management medical practices.

Results

In this study, hydrocodone was the most prescribed opiate. One of the reasons for performing medical urine drug tests is to determine if the patient is taking other non-prescribed drugs. For the pain treated patients the most observed drug was hydromorphone, this is a metabolite of hydrocodone, and morphine as well as a prescription drug. The incidence of illicit drug use was significant (about10%) However the use of alcohol as measured by the frequency of positive ETS in specimens was about 23% far greater than any other non-prescribed drug. We observed drugs not listed in the CLSI guidelines which included mitragynine, methylphenidate, fluoxetine, bupropion, meperidine, 6-betanaltrexol, naltrexone, naloxone, zolpidem, and phentermine.

Limitations

Our study was limited to the opiate drugs, hydrocodone, oxycodone, morphine, and the opiate agonists, methadone, buprenorphine. We also tested for the illicit drugs heroin, fentanyl, cocaine, and THCA.

Conclusion

The major drugs found were opiates showing compliance, however, alcohol use was prevalent, but the incidence of illicit drug use was low.

Acknowledgement

All the authors are employees of Precision Diagnostics LLC.

Conflict of Interest

There are no conflicts of interest.

Citation
Keywords
Signup for Newsletter
Scroll to Top